These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 22486716

  • 1. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma.
    Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH.
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1343-50. PubMed ID: 22486716
    [Abstract] [Full Text] [Related]

  • 2. Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma.
    Chan SL.
    Aliment Pharmacol Ther; 2012 Jul; 36(1):74-5; discussion 75. PubMed ID: 22650492
    [No Abstract] [Full Text] [Related]

  • 3. [Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session].
    El Khaddari S, Gaudin JL, Abidi H, Picaud G, Rode A, Souquet JC.
    Gastroenterol Clin Biol; 2002 Jul; 26(8-9):728-34. PubMed ID: 12434077
    [Abstract] [Full Text] [Related]

  • 4. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Liver Cancer Study Group of Japan.
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [Abstract] [Full Text] [Related]

  • 5. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
    Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M.
    J Hepatol; 2012 Apr; 56(4):886-92. PubMed ID: 22173160
    [Abstract] [Full Text] [Related]

  • 6. [Chemoembolization of hepatocellular carcinomas: which factors determine therapeutic response and survival?].
    Huppert PE, Lauchart W, Duda SH, Torkler C, Kloska SP, Weinlich M, Benda N, Pereira P, Claussen CD.
    Rofo; 2004 Mar; 176(3):375-85. PubMed ID: 15026951
    [Abstract] [Full Text] [Related]

  • 7. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre.
    Molinari M, Kachura JR, Dixon E, Rajan DK, Hayeems EB, Asch MR, Benjamin MS, Sherman M, Gallinger S, Burnett B, Feld R, Chen E, Greig PD, Grant DR, Knox JJ.
    Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):684-92. PubMed ID: 17100154
    [Abstract] [Full Text] [Related]

  • 8. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients.
    Yuen MF, Chan AO, Wong BC, Hui CK, Ooi GC, Tso WK, Yuan HJ, Wong DK, Lai CL.
    Am J Gastroenterol; 2003 May; 98(5):1181-5. PubMed ID: 12809846
    [Abstract] [Full Text] [Related]

  • 9. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).
    Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L, Fédération Francophone de Cancérologie Digestive.
    Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076
    [Abstract] [Full Text] [Related]

  • 10. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N, Osuga K, Higashihara H, Tomoda K, Mikami K, Nakazawa T, Nakamura H, Tomiyama N.
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [Abstract] [Full Text] [Related]

  • 11. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma.
    O'Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, Fan ST.
    Br J Surg; 2003 Mar; 90(3):325-31. PubMed ID: 12594668
    [Abstract] [Full Text] [Related]

  • 12. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.
    Favelier S, Boulin M, Hamza S, Cercueil JP, Cherblanc V, Lepage C, Hillon P, Chauffert B, Krausé D, Guiu B.
    Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1039-46. PubMed ID: 23224215
    [Abstract] [Full Text] [Related]

  • 13. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation.
    Yang Z, Zou R, Zheng Y, Qiu J, Shen J, Liao Y, Zhang Y, Wang C, Wang Y, Yuan Y, Li K, Zuo D, He W, Liu W, Li B, Yuan Y.
    Eur Radiol; 2019 Nov; 29(11):5752-5762. PubMed ID: 30993438
    [Abstract] [Full Text] [Related]

  • 14. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival.
    Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ.
    Radiology; 2011 Feb; 258(2):627-34. PubMed ID: 21273524
    [Abstract] [Full Text] [Related]

  • 15. Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients.
    Dumortier J, Chapuis F, Borson O, Davril B, Scoazec JY, Poncet G, Henry L, Boillot O, Mion F, Berger F, Partensky C, Paliard P, Valette PJ.
    Dig Liver Dis; 2006 Feb; 38(2):125-33. PubMed ID: 16389002
    [Abstract] [Full Text] [Related]

  • 16. [Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis--experiences].
    Herber S, Pitton M, Mönch C, Schneider J, Manzl N, Kummer I, Kanzler S, Schuchmann M, Junginger T, Düber C, Otto G.
    Zentralbl Chir; 2007 Aug; 132(4):306-15. PubMed ID: 17724633
    [Abstract] [Full Text] [Related]

  • 17. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
    Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, Chung YH, Lee YS, Lee SG, Park JH, Suh DJ.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):2004-11. PubMed ID: 21621346
    [Abstract] [Full Text] [Related]

  • 18. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS, Park MH, Jeon GS.
    Acta Radiol; 2011 Apr 01; 52(3):331-5. PubMed ID: 21498371
    [Abstract] [Full Text] [Related]

  • 19. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L, Shusang V, Buscombe JR, Cholongitas E, Stigliano R, Davies N, Tibballs J, Patch D, Meyer T, Burroughs AK.
    J Nucl Med; 2009 Jun 01; 50(6):871-7. PubMed ID: 19443599
    [Abstract] [Full Text] [Related]

  • 20. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
    Heng-jun G, Yao-jun Z, Min-shan C, Mei-xian C, Jun-ting H, Li X, Lau WY.
    Liver Int; 2014 Apr 01; 34(4):612-20. PubMed ID: 24028297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.